These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3569027)

  • 1. Tobramycin elimination rate change from first to later doses in older cystic fibrosis patients.
    Horner GW; Stempel DA
    Drug Intell Clin Pharm; 1987 Mar; 21(3):276-8. PubMed ID: 3569027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Individualization of tobramycin dosage in patients with cystic fibrosis.
    Hsu MC; Aguila HA; Schmidt VL; Munzenberger PJ; Kauffman RE; Polgar G
    Pediatr Infect Dis; 1984; 3(6):526-9. PubMed ID: 6440126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis.
    Mann HJ; Canafax DM; Cipolle RJ; Daniels CE; Zaske DE; Warwick WJ
    Pediatr Pulmonol; 1985; 1(5):238-43. PubMed ID: 4069813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
    Horrevorts AM; de Witte J; Degener JE; Dzoljic-Danilovic G; Hop WC; Driessen O; Michel MF; Kerrebijn KF
    Chest; 1987 Nov; 92(5):844-8. PubMed ID: 3665599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.
    Winnie GB; Cooper JA; Witson J; Cowan RG; Mayer D; Lepow M
    Pediatr Infect Dis J; 1991 May; 10(5):381-6. PubMed ID: 1906161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
    McCrae WM; Raeburn JA; Hanson EJ
    J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
    Staubes BA; Metzger NL; Walker SD; Peasah SK
    Pharmacotherapy; 2016 Jun; 36(6):623-30. PubMed ID: 27138730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.
    Cheer SM; Waugh J; Noble S
    Drugs; 2003; 63(22):2501-20. PubMed ID: 14609360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequential ciprofloxacin therapy in pediatric cystic fibrosis: comparative study vs. ceftazidime/tobramycin in the treatment of acute pulmonary exacerbations. The Cystic Fibrosis Study Group.
    Church DA; Kanga JF; Kuhn RJ; Rubio TT; Spohn WA; Stevens JC; Painter BG; Thurberg BE; Haverstock DC; Perroncel RY; Echols RM
    Pediatr Infect Dis J; 1997 Jan; 16(1):97-105; discussion 123-6. PubMed ID: 9002118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis.
    Bauer LA; Piecoro JJ; Wilson HD; Blouin RA
    Clin Pharm; 1983; 2(3):262-4. PubMed ID: 6883955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
    Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
    Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population Pharmacokinetics of Tobramycin Inhalation Solution in Pediatric Patients With Cystic Fibrosis.
    Wang X; Koehne-Voss S; Anumolu SS; Yu J
    J Pharm Sci; 2017 Nov; 106(11):3402-3409. PubMed ID: 28634121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis.
    Barclay ML; Begg EJ; Chambers ST; Thornley PE; Pattemore PK; Grimwood K
    J Antimicrob Chemother; 1996 Jun; 37(6):1155-64. PubMed ID: 8836818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
    Crozier DN; Khan SR
    J Infect Dis; 1976 Aug; 134 Suppl():S187-90. PubMed ID: 823275
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis.
    Hoogkamp-Korstanje JA; van der Laag J
    J Antimicrob Chemother; 1983 Aug; 12(2):175-83. PubMed ID: 6619055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of high-dose tobramycin-carbenicillin therapy in pseudomonal infections in cystic fibrosis.
    Fraser GL; Valenti AJ; Grimes GR; Corbin RP
    Drug Intell Clin Pharm; 1985 Oct; 19(10):757-61. PubMed ID: 4053983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring.
    Bartel K; Habash T; Lugauer S; Bärmeier H; Böwing B; Unsal M; Schoerner C; Heininger U
    Infection; 1999; 27(4-5):268-71. PubMed ID: 10885841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.